These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12114415)

  • 41. A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
    Salazar R; Bissett D; Twelves C; Breimer L; DeMario M; Campbell S; Zhi J; Ritland S; Cassidy J
    Clin Cancer Res; 2004 Jul; 10(13):4374-82. PubMed ID: 15240525
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
    Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee.
    Twelves CJ; Gardner C; Flavin A; Sludden J; Dennis I; de Bono J; Beale P; Vasey P; Hutchison C; Macham MA; Rodriguez A; Judson I; Bleehen NM
    Br J Cancer; 1999 Aug; 80(11):1786-91. PubMed ID: 10468297
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors.
    Ramnath N; Schwartz GN; Smith P; Bong D; Kanter P; Berdzik J; Creaven PJ
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):227-30. PubMed ID: 12655441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.
    Rees C; Beale P; Trigo JM; Mitchell F; Jackman A; Smith R; Douglass E; Judson I
    Clin Cancer Res; 2003 Jun; 9(6):2049-55. PubMed ID: 12796367
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
    Mita AC; Denis LJ; Rowinsky EK; Debono JS; Goetz AD; Ochoa L; Forouzesh B; Beeram M; Patnaik A; Molpus K; Semiond D; Besenval M; Tolcher AW
    Clin Cancer Res; 2009 Jan; 15(2):723-30. PubMed ID: 19147780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
    ; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
    J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors.
    Rodriguez GI; Jones RE; Orenberg EK; Stoltz ML; Brooks DJ
    Clin Cancer Res; 2002 Sep; 8(9):2828-34. PubMed ID: 12231523
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
    J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
    Dupont J; Bienvenu B; Aghajanian C; Pezzulli S; Sabbatini P; Vongphrachanh P; Chang C; Perkell C; Ng K; Passe S; Breimer L; Zhi J; DeMario M; Spriggs D; Soignet SL
    J Clin Oncol; 2004 Aug; 22(16):3366-74. PubMed ID: 15310782
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
    Cunningham C; Appleman LJ; Kirvan-Visovatti M; Ryan DP; Regan E; Vukelja S; Bonate PL; Ruvuna F; Fram RJ; Jekunen A; Weitman S; Hammond LA; Eder JP
    Clin Cancer Res; 2005 Nov; 11(21):7825-33. PubMed ID: 16278405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
    Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
    Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.
    Rademaker-Lakhai JM; Horenblas S; Meinhardt W; Stokvis E; de Reijke TM; Jimeno JM; Lopez-Lazaro L; Lopez Martin JA; Beijnen JH; Schellens JH
    Clin Cancer Res; 2005 Mar; 11(5):1854-62. PubMed ID: 15756010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer.
    Adjei AA; Reid JM; Erlichman C; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Ruben S; Boemer SA; Atherton P; Ames MM; Kaufmann SH
    Invest New Drugs; 2002 Aug; 20(3):297-304. PubMed ID: 12201492
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.
    Galanis E; Buckner JC; Maurer MJ; Reid JM; Kuffel MJ; Ames MM; Scheithauer BW; Hammack JE; Pipoly G; Kuross SA
    Invest New Drugs; 2005 Oct; 23(5):495-503. PubMed ID: 16133802
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.
    Kestell P; Dunlop IC; McCrystal MR; Evans BD; Paxton JW; Gamage RS; Baguley BC
    Cancer Chemother Pharmacol; 1999; 44(1):45-50. PubMed ID: 10367748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma.
    Zalupski MM; Philip PA; LoRusso P; Shields AF
    Cancer Chemother Pharmacol; 1997; 40(3):225-7. PubMed ID: 9219505
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
    Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
    Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I and pharmacokinetic study of flavone acetic acid.
    Kerr DJ; Kaye SB; Cassidy J; Bradley C; Rankin EM; Adams L; Setanoians A; Young T; Forrest G; Soukop M
    Cancer Res; 1987 Dec; 47(24 Pt 1):6776-81. PubMed ID: 3677106
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.
    Paridaens R; Uges DR; Barbet N; Choi L; Seeghers M; van der Graaf WT; Groen HJ; Dumez H; Buuren IV; Muskiet F; Capdeville R; Oosterom AT; de Vries EG
    Br J Cancer; 2000 Sep; 83(5):594-601. PubMed ID: 10944598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.